A randomized trial to test the hypothesis that short-term pharmacological reversal of
electrical remodeling after cardioversion is equally efficient to prevent recurrent atrial
fibrillation as standard long-term antiarrhythmic therapy.
Phase:
N/A
Details
Lead Sponsor:
Atrial Fibrillation Network German Atrial Fibrillation Network
Collaborators:
German Federal Ministry of Education and Research German Research Foundation Meda Pharmaceuticals